NIVF vs NTRA vs PGNY vs TMHC vs HIMS

For growth investors, Hims & Hers Health, Inc.

(HIMS) is the stronger pick with 59. 0% revenue growth year-over-year, versus -0. 6% for Taylor Morrison Home Corporation (TMHC). Taylor Morrison Home Corporation (TMHC) offers the better valuation at 7. 7x trailing P/E (11. 2x forward), making it the more compelling value choice. Analysts rate Natera, Inc. (NTRA) a "Buy" — based on 27 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Taylor Morrison Home Corporation (TMHC) is the cheapest at 7.

7x versus Hims & Hers Health, Inc. at 50. 3x. On forward P/E, Taylor Morrison Home Corporation is actually cheaper at 11. 2x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Taylor Morrison Home Corporation wins at 0. 34x versus Progyny, Inc. 's 2. 45x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Hims & Hers Health, Inc.

(HIMS) delivered a total return of +137. 6%, compared to -100. 0% for NewGenIvf Group Limited (NIVF). Over 10 years, the gap is even starker: NTRA returned +20. 9% versus NIVF's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Progyny, Inc.

(PGNY) is the lower-risk stock at 0. 71β versus Hims & Hers Health, Inc. 's 2. 40β — meaning HIMS is approximately 239% more volatile than PGNY relative to the S&P 500. On balance sheet safety, Progyny, Inc. (PGNY) carries a lower debt/equity ratio of 5% versus 2% for Hims & Hers Health, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Hims & Hers Health, Inc.

(HIMS) is pulling ahead at 59. 0% versus -0. 6% for Taylor Morrison Home Corporation (TMHC). On earnings-per-share growth, the picture is similar: Progyny, Inc. grew EPS 14. 0% year-over-year, compared to -279. 4% for NewGenIvf Group Limited. Over a 3-year CAGR, HIMS leads at 64. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Taylor Morrison Home Corporation (TMHC) is the more profitable company, earning 9.

6% net margin versus -9. 7% for NewGenIvf Group Limited — meaning it keeps 9. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TMHC leads at 14. 0% versus -21. 4% for NIVF. At the gross margin level — before operating expenses — NTRA leads at 64. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Taylor Morrison Home Corporation (TMHC) is the more undervalued stock at a PEG of 0. 34x versus Progyny, Inc. 's 2. 45x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Taylor Morrison Home Corporation (TMHC) trades at 11. 2x forward P/E versus 51. 5x for Hims & Hers Health, Inc. — 40. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PGNY: 60. 8% to $30. 80.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Taylor Morrison Home Corporation (TMHC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

92), +321. 2% 10Y return). NewGenIvf Group Limited (NIVF) carries a higher beta of 1. 96 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (TMHC: +321. 2%, NIVF: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (NIVF (Healthcare) and NTRA (Healthcare) and PGNY (Healthcare) and TMHC (Consumer Cyclical) and HIMS (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: NIVF is a small-cap quality compounder stock; NTRA is a mid-cap high-growth stock; PGNY is a small-cap quality compounder stock; TMHC is a small-cap deep-value stock; HIMS is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.